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Abstract. The goal of the REMINE project is to build a high performance 
prediction, detection and monitoring platform for managing Risks against Patient 
Safety (RAPS). Part of the work involves developing an ontology enabling 
computer-assisted RAPS decision support in the context of the disease history of a 
patient as documented in a hospital information system. A requirement of the 
ontology is to contain a representation for what is commonly referred to by the 
term ‘adverse event’, one challenge being that distinct authoritative sources define 
this term in slightly different ways and utterly context-dependent. The presence of 
some common ground in all definitions is, however, obvious. Using the analytical 
principles underlying Basic Formal Ontology and Referent Tracking, both 
developed in the tradition of philosophical realism, we propose a formal 
representation of this common ground which involves the combination of a 
reference ontology consisting exclusively of universals and an application 
ontology which consists of defined classes. We argue that what in most cases is 
referred to by means of the term ‘adverse event’ – when used generically – is a 
defined class rather than a universal. In favour for adverse event as a defined class 
are the arguments that (1) there is no definition for ‘adverse event’ that carves out 
a collection of particulars which constitutes the extension of a universal, and (2) 
the majority of definitions require adverse events to be (variably) the result of 
some observation, assessment or (absence of) expectation thereby giving these 
entities a nominal or epistemological flavour. 
Keywords. Basic Formal Ontology, Referent Tracking, adverse events, patient 
safety. 
1. Introduction 
‘High performance prediction, detection and monitoring platform for patient safety risk 
management (REMINE)’ is the name of a European Large Scale Integrating Project 
(IP) funded by the European Commission since Jan 1, 2008 [1]. The main objective is 
to develop a technological platform and best practice business processes allowing 
automated management and prevention of Risks against Patient Safety (RAPS). 
Part of the work to be carried out consists of the development of an ontology that 
will support several functionalities offered by the envisioned technological platform. In 
this paper, we focus on one particular RAPS issue: adverse events. 
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Table 1. Adverse event related definitions from authoritative sources 
ID Term Definition Source Ref. 
D1 adverse drug 
event 
(adverse 
drug error)  
Any incident in which the use of a medication (drug or 
biologic) at any dose, a medical device, or a special 
nutritional product (for example, dietary supplement, infant 
formula, medical food) may have resulted in an adverse 
outcome in a patient. 
JTC [2] 
D2 adverse drug 
experience 
any adverse event associated with the use of a drug in 
humans, whether or not considered drug related, including 
the following:  
• an adverse event occurring in the course of the 
use of a drug product in professional practice;  
• an adverse event occurring from drug overdose 
whether accidental or intentional;  
• an adverse event occurring from drug abuse;  
• an adverse event occurring from drug 
withdrawal; and  
• any failure of expected pharmacological action. 
FDA [3] 
D3 adverse drug 
reaction 
an undesirable response associated with use of a drug that 
either compromises therapeutic efficacy, enhances toxicity, 
or both. 
JTC [2] 
D4 adverse 
event 
an observation of a change in the state of a subject assessed 
as being untoward by one or more interested parties within 
the context of a protocol-driven research or public health. 
BRIDG [4] 
D5 adverse 
event 
an event that results in unintended harm to the patient by an 
act of commission or omission rather than by the underlying 
disease or condition of the patient 
IOM [5] 
D6 adverse 
event 
any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medical treatment or 
procedure that may or may not be considered related to the 
medical treatment or procedure  
NCI [6] 
D7 adverse 
event 
any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product 
and which does not necessarily have to have a causal 
relationship with this treatment 
CDISC [7] 
D8 adverse 
event  
an untoward, undesirable, and usually unanticipated event, 
such as death of a patient, an employee, or a visitor in a 
health care organization. Incidents such as patient falls or 
improper administration of medications are also considered 
adverse events even if there is no permanent effect on the 
patient. 
JTC [2] 
D9 adverse 
event 
an injury that was caused by medical management and that 
results in measurable disability. 
QUIC [8] 
D10 error of 
omission 
An error which occurs as a result of an action not taken. 
Errors of omission may or may not lead to adverse 
outcomes. 
JTC [2] 
D11 observation an act of recognizing and noting a fact or an occurrence of 
an event of interest. An observation may involve 
examination, interviews, or measurement with devices. 
Observations are not intended to alter the state of the subject. 
BRIDG [4] 
D12 serious 
adverse drug 
experience 
Any adverse drug experience occurring at any dose that 
results in any of the following outcomes:  
• death,  
• a life-threatening adverse drug experience,  
• inpatient hospitalization 
• prolongation of existing hospitalization,  
• a persistent or significant disability/incapacity,  
• a congenital anomaly/birth defect.  
FDA [3] 
[9] 
The term ‘adverse event’ is in the literature defined in a variety of ways, 
superordinate terms frequently used being ‘reaction’, ‘effect’, ‘event’, ‘problem’, 
‘experience’, ‘injury’, ‘symptom’, ‘illness’, ‘occurrence’, ‘change’, and even 
‘something’, ‘act’, ‘observation’ and ‘term’, the latter four being the result of applying 
flawed terminological theories [10]. This multitude of definitions is brought about by 
the many organisations and initiatives that set the noble goal to reduce the occurrence 
of adverse events since the Institute of Medicine published its report ‘To Err is Human: 
Building a Safer Health System’ [11]. Table 1 contains a small selection of adverse 
event definitions by authoritative sources, drawn from a larger collection that we 
composed for our work [12]. 
Research aimed to bring some order in this domain falls in three categories. One is 
classification, as witnessed by the work of Chang et al. who developed – based on a set 
of criteria [13] – a classification schema consisting of five root nodes which were 
found to be the ‘homogeneous elements’ encountered in relevant sources: Impact, Type, 
Domain, Cause and Prevention and Mitigation [14]. Others, such as the BRIDG 
consortium, have tried to get rid of the multitude of definitions by reaching consensus 
on just one [4], with the result of being extremely reductionist. A third group of 
researchers focuses on building ontologies, most often, unfortunately, by using the very 
weak principles underlying ‘concept’-orientation [15], such that, for example, ‘age’ 
and ‘gender’ become a subclass of ‘patient’ [16].  
With researchers of the third group, we believe that ‘ontology’ is indeed the right 
approach, but, in contrast to them, only when rigorous principles that go far beyond 
computational soundness are applied. 
2. Objective and design 
Our goal is to bring clarity in the terminological wilderness that grew out of all these 
efforts not only because of differences amongst initiatives in terms of scope, involved 
health care settings, jurisdictions, and objectives – the consequence being that 
definitions resulting from such efforts are not applicable outside the original boundaries 
– but also, for a large number of them, because of the failure to adopt sound ontological 
and terminological principles in analysing and conveying what is relevant. A definition 
such as “ ‘Adverse outcome’ should be understood to mean not only a non-trivial 
adverse outcome […] but also an incident […] which results in a recognized potential 
risk of a non-trivial adverse outcome […]” [17] (irrelevant detail omitted), is of the 
form ‘an X is an X or a Y which leads to an X’ and is thus clearly uninformative. 
To obtain our goal, we analysed the literature and collected all relevant definitions 
and descriptions that we found. We modified some of these definitions slightly in order 
to have them convey better what we judged to be the intended message. 
We also studied a variety of classification systems, taxonomies, terminologies and 
concept-based ontologies – we use the term ‘concept-based ontologies’ to differentiate 
such representational artifacts clearly from the realism-based ontology that is being 
developed under REMINE – in order to obtain a comprehensive list of entity types 
whose nature and interrelationships are to be studied and formally represented to 
satisfy the REMINE requirements. 
3. Methodology 
We performed our analysis following the principles advocated in Basic Formal 
Ontology and Referent Tracking.  
3.1. Basic Formal Ontology 
Basic Formal Ontology (BFO) is a framework encapsulating best practices in ontology 
development that is designed to serve as basis for the creation of high-quality shared 
ontologies in the biomedical domain [18, 19]. BFO acknowledges only those entities 
which exist in biological reality, and rejects all types of putative entities which are 
postulated merely as artifacts of specific logical or computational frameworks. BFO 
captures a small number of basic categories into which reality is divided thereby 
distinguishing at the highest level of its organisation (1) particulars such as Werner 
Ceusters from universals such as HUMAN BEING,2 (2) continuants such as Werner 
Ceusters’ heart from occurrents such as the beating of Werner Ceusters’ heart, and 
(3) independent entities such as Werner Ceusters’ heart from dependent entities such 
as the function of Werner Ceusters’ heart, the latter being such that they cannot exist 
– in the ontological rather than biological sense – without some instance of the former. 
BFO also distinguishes three major families of relations between entities in the 
categories just distinguished: (1) <p, p>-relations: from particular to particular (for 
example: Werner Ceusters’ s brain being part of Werner Ceusters); (2) <p, u>-
relations: from particular to universal (for example: Werner Ceusters being an instance 
of HUMAN BEING); and (3) <u, u>-relations: from universal to universal (for example: 
HUMAN BEING being a subkind of ORGANISM) [20]. 
3.2. Referent Tracking 
Referent tracking has been introduced as a new paradigm for entry and retrieval of data 
in the Electronic Health Record (EHR) to avoid the multiple ambiguities that arise 
when statements in an EHR refer to disorders, lesions and other entities on the side of 
the patient exclusively by means of generic terms from a terminology or ontology [21]. 
Referent tracking avoids such ambiguities by introducing IUIs –Instance Unique 
Identifiers – for each numerically distinct entity that exists in reality and that is referred 
to in statements in the record. 
Drawing on this framework, we have proposed a calculus for use in quality 
assurance of the complex representations created for clinical or research purposes, for 
example in coding of clinical trial data [22]. The calculus is based on a distinction 
between three levels [23]: (1) the level of reality (for example, in the medical domain, 
the reality on the side of the patient); (2) the cognitive representations of this reality for 
example as embodied in observations and interpretations on the part of clinicians and 
others; (3) the publicly accessible concretizations of these cognitive representations in 
artifacts of various sorts, of which ontologies and terminologies and Electronic Health 
Records are examples.  
                                                          
2 For clarity, we will from here on represent particulars in bold italic and universals in SMALL CAPS. Terms 
(or other representational units) denoting either universals or particulars will be written in italics between 
single quotes. For additional clarity, we will sometimes use the words ‘particular’, ‘universal’ and ‘term’ 
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4. Results 
4.1. Terminological conventions 
In line with the terminology proposed in [23], we will further use the term ‘class’ to 
denote a collection of all and only those particulars to which a given general term 
applies. A class can either be (1) the extension of a universal, thus comprehending all 
and only those particulars which instantiate the corresponding universal (at that time) 
or (2) a subset of the extension of a universal defined as being such that the members of 
this class exhibit an additional property which is (a) not shared by all instances of the 
universal, and (b) also (can be) exhibited by particulars which are not instances of that 
universal. For such a class, we reserve the term ‘defined class’. By ‘property’, we mean 
either a monadic quality or a relationship that a particular enjoys with another 
particular or a universal. By ‘portion of reality’ we mean any combination of 
particulars (including classes and defined classes), universals and properties. We will 
use the term ‘representational unit’ (RU) for any symbolic representation (a code, a 
character string, an icon, …) which denotes a portion of reality. Table 2 gives an 
overview of the type of representational artifacts that are useful for representing 
portions of reality and what sort of entities should be represented in each type of 
artifact. The latter is inspired by the view that reference ontologies should be the 
equivalent of scientific theories and therefore should represent what is generic in the 
world – whether or not in a specific domain – in a way that maximizes faithfulness and 
comprehensiveness with respect to reality. Application ontologies, in contrast, 
represent matters in a format that is more suitable for computation [24]. Examples of 
inventories are databases which store information about particulars, examples being 
Electronic Health Records or Adverse Event Registries. 
4.2. Core representational units 
Table 3 shows the minimal collection of classes related to entities in reality that must 
be taken into consideration for being able to represent the portion of reality around a 
particular patient on whose side an adverse event might have occurred in line with any 
of the definitions for adverse event and related notions analyzed thus far. The 
descriptions provided are not to be interpreted as definitions for the terms that we 
choose to use as denotations for the corresponding entities, but rather illustrate the roles 
played by various entities in a scenario in which an adverse event might have occurred. 
 
Table 2: representational artifacts and their suggested representational units 
Representational artifact Contains representational units for … 
Reference Ontology • universals 
• relationships between universals along the principles of 
the Relation Ontology [20] 
Application Ontology • universals 
• defined classes 
• relationships between universals and defined classes 
along the principles of the Relation Ontology [20] 
• particulars required for defining defined classes 
Inventory • particulars 
• properties 
Table 3: Universals and Defined Classes for the adverse events domain. 
 Denotation Class 
Type 
Particular 
Type 
Description (role in adverse event scenario) 
Level 1 
C1 subject of care DC independent 
continuant 
person to whom harm might have been done 
through an act under scrutiny 
C2 act under scrutiny DC act of care act of care that might have caused harm to the 
subject of care 
C3 act of care U process activity carried out by a care giver to a subject of 
care, motivated by an underlying disease and a 
care intention, 
C4 care giver DC independent 
continuant 
person that performed an act of care to the subject 
of care 
C5 underlying 
disease 
DC dependent 
continuant 
the disease in the subject of care which is part of 
the motivation for why the act of care is performed 
C6 involved 
structure 
DC independent 
continuant 
anatomical structure (of the subject of care) 
involved in an act of care 
C7 structure change U process change in an anatomical structure of a person 
C8 structure integrity U dependent 
continuant 
quality of an anatomical structure which 
determines the types of circumstances under which 
the anatomical structure would become 
dysfunctional if such circumstances were present 
C9 integrity change U structure 
change 
change in the structure integrity of an anatomical 
structure such that there are after the change a 
different number of types of circumstances under 
which the anatomical structure would become 
dysfunctional, than before the change 
C10 harm U integrity 
change 
change in the structure integrity of an anatomical 
structure such that there are after the change more 
types of circumstances than before under which the 
anatomical structure will become dysfunctional 
C11 care effect DC integrity 
change 
integrity change brought about by an act of care 
C12 subject 
investigation 
DC process looking for a structure change  
C13 harm assessment U process pondering whether an observation is faithful to 
reality, and if so, whether the structure change 
denoted by the observation is a harm 
C14 care intention DC dependent 
continuant 
intention of a care giver that motivates him 
towards an act of care 
Level 2 
C15 observation DC dependent 
continuant 
cognitive representation about a structure change 
resulting from a subject investigation 
C16 harm diagnosis DC dependent 
continuant 
cognitive representation, resulting from a harm 
assessment, denoting whether a structure change 
is a harm 
C17 care effect belief DC dependent 
continuant 
belief on the side of the care giver concerning the 
care effects that he ascribes to the act of care 
Level 3 
C18 care reference DC information 
entity 
concretized (through text, diagram, …) piece of 
knowledge drawn from state of the art principles 
that can be used to support the appropriateness of 
(or correctness with which) processes are 
performed involving a subject of care 
Legend. Denotation: generic term applicable to a member of the class. Class type: indicates whether the 
class is the extension of a universal (U) or a defined class (DC). Particular type: indicates what sort of 
particulars, in terms of Basic Formal Ontology, members of the corresponding class are. 
Neither should any of the terms listed under the denotation-column by analysed outside 
the context of this paper. As an example, we do not claim that anything which by third 
parties would be referred to by means of the term ‘observation’ falls under the 
description that we provided. The conditionals that are used in most of these 
descriptions reflect the fact that a particular portion of reality might be such that a 
phenomenon which is considered to be an adverse event under one definition, is not an 
adverse event in terms of another definition. The conditionals, excluding a few obvious 
exceptions, should not be interpreted as having to do with probabilities or uncertainty. 
4.3. The place of ‘adverse events’ 
The representational units for the core classes identified above can be used to represent 
all possible portions of reality in which figures an entity that can be referred to by 
means of the term ‘adverse event’ under any of the definitions that we encountered. As 
an example, Table 4 lists the particulars and associated properties involved in a case in 
which a patient, born at time t0, under anti-inflammatory treatment and physiotherapy 
since t2 for arthrosis which is present since t1, develops a stomach ulcer at t3. The 
relationships for the properties are drawn from [20, 25], thereby keeping the format 
conventions proposed in [20], except for particulars which we pick out in bold italic. 
We introduce the primitive is_about relation holding between a representational unit 
and the entity in reality that this unit denotes at a certain time. We further make 
shortcuts in the representation of the temporal relationships by simply stating here that 
t0 earlier t1 earlier t2 earlier t3. We also allow for more temporal annotations than in 
[20], yet remaining faithful to EN 12388:2005: Health informatics - Time standards for 
healthcare specific problems [26]. 
Under this scenario, #10, i.e. the appearance of #9, would (at least probably – see 
discussion for some problematic issues with the wide variation in interpretations that 
can be given to the majority of the definitions) qualify as an adverse event as defined 
by the Institute of Medicine (definition D5). 
 
Table 4: Example of an adverse event case analysis 
IUI Particular description Properties 
#1 the patient who is treated #1 member C1 since t2 
#2 #1’s treatment #2 instance_of C3 
#2 has_participant #1 since t2 
#2 has_agent #3 since t2 
#3 the physician responsible for #2 #3 member C4 since t2 
#4 #1’s arthrosis #4 member C5 since t1 
#5 #1’s anti-inflammatory treatment  #5 part_of #2 
#5 member C2 since t3 
#6 #1’s physiotherapy #6 part_of #2 
#7 #1’s stomach #7 member C6 since t2 
#8 #7’s structure integrity #8 instance_of C8 since t0 
#8 inheres_in #7 since t0 
#9 #1’s stomach ulcer #9 part_of #7 since t3 
#10 coming into existence of #9 #10 has_participant #9 at t3 
#11 change brought about by #9 #11 has_agent #9 since t3 
#11 has_participant #8 since t3 
#11 instance_of C10 at t3 
#12 noticing the presence of #9 #12 has_participant #9 at t3+x 
#12 has_agent #3 at t3+x 
#13 cognitive representation in #3 about #9 #13 is_about #9 since t3+x 
However, for definition D9, it would rather be #9 itself, while for D4, proposed by 
the BRIDG consortium [4], it would be either #12 or #13. The unclarity in the latter 
case is brought about by the confusions and conflations in the HL7 RIM [27] upon 
which BRIDG is heavily inspired. 
Because of the various sorts of entities that qualify as adverse events depending on 
which definition is used, at least two adverse event classes need to be defined: one for 
adverse events under views that see adverse events as processes, and one for adverse 
events as continuants. A further distinction has to be made between adverse events as 
entities in first order reality, and phenomena in first order reality that, as posited by 
some definitions, can only be qualified as adverse events by resorting to cognitive 
representations or by subjecting first order phenomena to an analysis dictated by 
scientific theories. 
5. Discussion 
Already a very superficial analysis of the definitions in Table 1, thereby applying the 
analytical principles just sketched, demonstrates that the question “What are adverse 
events?” cannot be answered directly, but needs to be reformulated as “What might the 
author of a particular sentence containing the phrase ‘adverse event’ refer to by that 
phrase?”. Indeed, the authors of these definitions must have had very distinct entities in 
mind: we cannot imagine any single entity to be such that if it were in front of the eyes 
of these authors, they would each in turn be able to point to it while the first author 
would say – faithfully and honestly – “that is an observation”, the second one: “that is 
a disease”, the third one: “that is a laboratory finding”, and so forth. Clearly, nothing 
which is a disease can be a laboratory finding, although, of course, laboratory findings 
can aid in diagnosing a disease or in monitoring its evolution. Similarly, nothing which 
is a laboratory finding, can be an observation, although, of course, some observation 
must have been made (either by a human being or a device) to come to a laboratory 
finding. However, because all authors use the term ‘adverse event’ in some context for 
each of these distinct entities, and because these contexts look quite similar – in each of 
them, more or less the same sort of entities seem to be involved – there is some 
common ground (a portion of reality) which is such that parts of it can be used as 
referents for the various meanings of ‘adverse event’.  
5.1. Classifying adverse event related entities in terms of the three levels of reality 
The definitions for the term ‘adverse event’ and other closely related terms differ in the 
ways that they require a representation which resorts to one, two or all three levels of 
reality as described above. The first part of D12 (from the Food and Drug 
Administration) is an example in which all terms refer to level 1 entities: drugs, drug 
doses, deaths, hospitalizations, disabilities, and so forth, are all entities that exist in 
first order reality. Another example is D9: the terms ‘injury’, ‘medical management’, 
‘measurement’ and ‘disability’, when used in the context of a specific patient that may 
or may not have experienced an adverse event, all denote existing entities on the side of 
that particular patient and his environment, and are not about something else: these 
terms thus denote level 1 entities. D2, in contrast, requires bringing level 2 and perhaps 
even level 3 entities into the picture, and this because of the clause ‘any failure of 
expected pharmacological action’. Expectations can only be raised by a cognitive 
being and are part of the cognitive representation this cognitive being has constructed 
about first order reality. Thus, in this interpretation of D2, i.e. if the expectation 
concerning the pharmacological action is ‘in the mind’ of the particular clinician 
assessing whether the patient has an adverse drug experience, D2 involves a level 2 
entity. However, if this expectation is something which is part of ‘general knowledge’ 
or belongs to the ‘state of the art’, then we are dealing with an additional level 3 entity: 
in order for the clinician assessing the case to have access to that ‘general knowledge’, 
it must have been concretized in some enduring fashion. 
5.2. Lack of clarity in definitions 
D2 exhibits a characteristic which, unfortunately, is shared by the majority of the 
definitions encountered: they lack sufficient clarity of phrasing to allow an analysis in 
realist terms to be conducted unproblematically. Often various interpretations can be 
given to one or more terms used within a definition whereby each interpretation 
suggests a denotation at a distinct level of reality. An example is definition D3 in which 
the term ‘undesirable’ can be interpreted in two different ways: (1) denoting something 
in level 1, a realizable such as a disposition or tendency [28], such that the event results 
objectively in an increased health risk – thus any event ‘that either compromises 
therapeutic efficacy, enhances toxicity, or both’ is undesirable; (2) denoting something 
in level 2 such that amongst those events which influence therapeutic efficacy or 
toxicity only some are considered undesirable (for whatever reason) by either the 
patient, the caregiver or both, or (3) denoting something relative to level 3 to the effect 
that the particular event which occurs at level 1 is only undesirable when it is an 
instance of a type of event which is listed in some guideline, good practice 
management handbook, i.e. in something which is published about the state of the art in 
relevant matters. 
In other cases, this sort of analysis results in detecting hidden assumptions, 
conflations or even serious inconsistencies either within one definition or in the 
combination of several definitions offered by the same source. 
An example of an inconsistency in realist terms within one definition would result 
from the literal interpretation of D5, more precisely concerning the term ‘act of 
omission’, especially if that term, as suggested by D10, does not denote something 
existing, or having existed in the past. In Referent Tracking terms, there would thus be 
nothing that can be assigned a IUI to. Indeed, ‘doing nothing’, so we believe, is a 
linguistic description (level 3 entity) that can be used adequately and meaningfully in 
reporting about a complex portion of reality (level 1 entity). But such use by itself 
doesn’t mean that the term denotes directly and totally a level 1 entity: whereas for the 
term ‘doing something’ there is a referent in first order reality, there is no such referent 
pointed to by the term ‘doing nothing’. 
Consider the example given in [5] in which ‘not testing a diabetic patient for 
HbA1c’ is stated to be an ‘act of omission’. This is because since the work of the 
Diabetes Quality Improvement Project [29, 30] it is considered bad practice not to do 
such a test at regular intervals [31]. But clearly, if only a patient’s disease (here the 
diabetes) and some adverse event exist as first order entities, then it is not possible that 
an ‘act of omission’, i.e. not doing something what one is supposed to do according to 
the state of the art, would be the cause of the adverse event, and it must thus be the 
underlying disease. Events, so we believe, can only be caused by what exists. In the 
diabetes case, it is, clearly, the diabetes that causes the adverse event, although it is true 
that if the test were taken, as well as further appropriate actions in line with the results 
of the test, it could be expected that no adverse event would have occurred. Therefore, 
a better definition for what D5 tries to denote would be: ‘an event that results in 
unintended harm to the patient (1) by an act of commission rather than by the 
underlying disease or condition of the patient, or (2) by the underlying disease or 
condition of the patient in absence of appropriate actions being taken in line with the 
state of the art in dealing with the disease’. This rephrased definition accounts better 
for something else the Institute of Medicine had probably in mind when producing D5, 
namely that many acts of commission are part of a procedure which for them being 
conducted ‘lege artis’ include taking actions that if they would not be taken, would lead 
to harm to the patient because of the act of commission. An example is incising an 
artery during some surgical procedure what inevitable leads to bleeding. It would be 
inappropriate, in such case, not to take actions to stop or reduce the bleeding. Here it is 
not the underlying disease which leads to harm to the patient, neither is it the ‘not 
stopping the bleeding’ which leads to the harm. Rather it is the bleeding caused by the 
incision. 
6. Conclusion 
We have used the principles of Basic Formal Ontology (BFO), the Relation Ontology 
(RO) and Referent Tracking (RT) as an analytical framework to study the ontological 
nature of what is denoted by the term ‘adverse event’. Our research indicates that this 
framework is adequate, and, when used appropriately, avoids the inconsistencies and 
incompatibilities inherent in other approaches. Nevertheless, some further 
developments, especially in RO are required to be able to deal more formally with 
some extensions that we proposed here: (1) an aboutness or denotation relation to 
relate level 2 and level 3 entities to level 1 entities, (2) a membership relation to link 
particulars to defined classes, and (3) the capacity to refer to (open-ended) time periods 
in addition to time instants. 
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